Drug-induced hearing loss as a manifestation of drug-induced ototoxicity

Остроумова, О Д; Chikh, E V; Реброва, Е. В.; Ryazanova, A. Yu.; Переверзев, А. П.

doi:10.17116/otorino20198404172

Cited by 8 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…), сосудистые расстройства (гипертоническая болезнь, ишемическая болезнь сердца, вертебробазиллярная дисциркуляция, нарушение реологических свойств крови и др. ), метаболические нарушения (сахарный диабет), токсические воздействия (промышленные, бытовые), ототоксичные лекарственные препараты (аминогликозидные антибиотики, петлевые диуретики, нестероидные противовоспалительные препараты, антиаритмические препараты, цитостатики), травма (механическая, акустическая и баротравма), аутоиммунное поражение внутреннего уха, органические заболевания головного мозга, стресс, генетическая предрасположенность, неблагоприятные условия труда (постоянное шумовое воздействие), острый и хронический гнойный средний отит [1,6,7,9,10,27,29,31,35,38,48].…”

Section: Conclusion the Data We Found In The Course Of Studying The S...unclassified

Sensorineural Hearing Loss: Prevalence and Features of the Organization of Medical Care

Abdullaeva

Popadyuk

Фомина

2022

SJLSA

View full text Add to dashboard Cite

Sensorineural hearing loss (SNHL) is a form of hearing loss, which today has medical, social and economic significance. According to the World Health Organization (WHO), today there is a rapid increase in the number of patients suffering from SNHL. As it is known, the success in the treatment of such patients depends on the beginning of the treatment time. Accordingly, it is very important to organize the medical care efficiently and in time, but it is not always possible to ensure this. For this, it is necessary to improve the otorhinolaryngological service and the health care system. Purpose. Based on the analysis of literature sources, consider the issues of the incidence of SNHL and present the main stages and problems of organizing medical care for patients with sensorineural hearing loss. Materials and methods. A search and analysis of scientific data on the research topic was carried out. The collection was carried out in Russian and foreign electronic data systems: eLIBRARY.ru, PubMed, cyberleninka.ru, Google Scholar, glav-otolar.ru, who.int/ru, rosstat.gov.ru. Conclusion. The data we found in the course of studying the scientific literature indicate the growing interest in this problem. Sensorineural hearing loss is a complex disease, due to the variety of possible etiological factors and the absence of a single etiopathogenesis. The procedure for organizing medical care for patients with SNHL at each stage of its provision is regulated by regulatory and legal acts. The study of morbidity, assessment of the quality of medical care makes it possible to determine the ways to improve the provision of medical care to patients suffering from SNHL.

show abstract

Section: Conclusion the Data We Found In The Course Of Studying The S...unclassified

Sensorineural Hearing Loss: Prevalence and Features of the Organization of Medical Care

Abdullaeva

Popadyuk

Фомина

2022

SJLSA

View full text Add to dashboard Cite

show abstract

“…Необходимость ранней диагностики определяется тем, что в ряде случаев существует возможность уменьшения ототоксического эффекта коррекцией режимов дозирования. В случае развившейся тугоухости необходимо своевременно начать сурдопедагогическую реабилитацию, слухопротезирование [1, 3,6,12].…”

Section: использование отоак устической эмис-сии д ля мониторинга ототоксичностиunclassified

Otoacoustic emissions: major trends in pediatric practice

et al. 2020

View full text Add to dashboard Cite

The high prevalence of hearing loss in children determines the need for reliable methods for the timely detection and diagnosis of hearing impairment at any age, starting from a birth. Otoacoustic emissions are widely used in hearing screening and audiological assessment as an objective tool for cochlear status evaluation. Over the past 30 years, their use in routine audiological assessments has increased significantly. Understanding the subtle processes that occur in the cochlea during the transmission of acoustic stimuli which generate otoacoustic emissions as well as knowledge about the registration parameters, otoacoustic emissions characteristics, otoacoustic emissions advantages and constraints are important for results analysis. Contemporary understanding of the occurrence of auditory sensations as well as the description of various types of otoacoustic emissions used in routine clinical practice (transient otoacoustic emissions and distorting product otoacoustic emissions) are presented in the review. The features of otoacoustic emissions using in pediatric practice are described: in newborns hearing screening, including the peculiarities of applying of this test for infants having had got their treatment in the intensive care units. Otoacoustic emissions significance for hearing diagnosis and as well as for ototoxicity monitoring is shown. Reliability, non-invasiveness, objectivity, simplicity of the otoacoustic emissions testing has done it one of the main methods both in hearing screening and diagnostics for children on any age.

show abstract

“…Drug-induced hearing loss mainly refers to the inner ear damage caused by drugs that can damage the auditory nervous system. , Platinum anticancer drugs recorded a high incidence of hearing loss in the clinic . Cisplatin (CDDP)-induced ototoxicity generally manifests in the form of irreversible, progressive, and bilateral sensorineural hearing loss, which causes the irreversible death of auditory cells by apoptosis and necrosis and leads to the apoptosis of hair cells (HCs). − Mammalian cochlear HCs are unable to regenerate once damaged, thereby resulting in permanent hearing loss .…”

Section: Introductionmentioning

confidence: 99%

Design, Synthesis, and Biological Evaluation of Dexamethasone–Salvianolic Acid B Conjugates and Nanodrug Delivery against Cisplatin-Induced Hearing Loss

Sun

Peng

et al. 2021

J. Med. Chem.

View full text Add to dashboard Cite

Cisplatin (CDDP) is an extensively used chemotherapeutic agent but has a high incidence of severe ototoxicity. Although a few molecules have entered clinical trials, none have been approved to prevent or treat CDDP-induced hearing loss by the Food and Drug Administration. In this study, an amphiphilic drug–drug conjugate was synthesized by covalently linking dexamethasone (DEX) and salvianolic acid B (SAL) through an ester or amide bond. The conjugates could self-assemble into nanoparticles (NPs) with ultrahigh drug loading capacity and favorable stability. Compared with DEX, SAL, or their physical mixture at the same concentrations, both conjugates and NPs showed enhanced otoprotection in vitro and in vivo. More importantly, the conjugates and NPs almost completely restored hearing in a guinea pig model with good biocompatibility. Immunohistochemical analyses suggested that conjugates and NPs activated the glucocorticoid receptor, which may work as one of the major mechanisms for their protective effects.

show abstract

Drug-induced hearing loss as a manifestation of drug-induced ototoxicity

Cited by 8 publications

References 36 publications

Sensorineural Hearing Loss: Prevalence and Features of the Organization of Medical Care

Sensorineural Hearing Loss: Prevalence and Features of the Organization of Medical Care

Otoacoustic emissions: major trends in pediatric practice

Design, Synthesis, and Biological Evaluation of Dexamethasone–Salvianolic Acid B Conjugates and Nanodrug Delivery against Cisplatin-Induced Hearing Loss

Contact Info

Product

Resources

About